Brief: GRI Bio Inc - Phase 2A Study Results For GRI-0621 Expected In Q2 2025
22/05/2025 13:33
May 22 (Reuters) - GRI Bio Inc GRI.O: GRI BIO INC - PHASE 2A STUDY RESULTS FOR GRI-0621 EXPECTED IN Q2 2025 Source text: ID:nGNXbFByd6 Further company coverage: GRI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on GRI Bio
See all newsGRI Bio Inc reports results for the quarter ended June 30 - Earnings Summary
GRI Bio Inc expected to post a loss of $1.19 a share - Earnings Preview
Brief: Gri Bio Secures FDA Orphan Drug Designation For Gri-0621 (Tazarotene) In Idiopathic Pulmonary Fibrosis
GRI Bio Q1 net loss narrows on lower R&D expenses
GRI Bio raises $14.5 mln to fund operations into Q1 2027